Polymorphisms of Potential Drug Resistant Molecular Markers in *Plasmodium Vivax* From China–Myanmar Border During 2008 to 2017

Zhen-sheng Wang

CAMS PUMC: Chinese Academy of Medical Sciences and Peking Union Medical College

Chun-yan Wei

CAMS PUMC: Chinese Academy of Medical Sciences and Peking Union Medical College

Yun-chun Pan

CAMS PUMC: Chinese Academy of Medical Sciences and Peking Union Medical College

Zhi-hua Wang

Guilin Medical University

Xin Ji

China Academy of Chinese Medical Sciences

Qianqian Chen

CAMS PUMC: Chinese Academy of Medical Sciences and Peking Union Medical College

Lian-hui Zhang

CAMS PUMC: Chinese Academy of Medical Sciences and Peking Union Medical College

Zenglei Wang (✉ zengleiwang@pumc.edu.cn)

Chinese Academy of Medical Sciences & Peking Union Medical College Institute of Pathogen Biology

Heng Wang

CAMS PUMC: Chinese Academy of Medical Sciences and Peking Union Medical College

Research Article

Keywords: Plasmodium vivax, antimalarial drugs, drug resistance, molecular markers, China-Myanmar border

Posted Date: January 24th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1278266/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Infectious Diseases of Poverty on April 25th, 2022. See the published version at <https://doi.org/10.1186/s40249-022-00964-2>.

Abstract

Background: *Plasmodium vivax* remains the predominant species at the China–Myanmar border, imposing a major challenge to the recent gains in regional malaria elimination. To closely supervise the emerging of drug resistance in this area, we surveyed the variations in genes potentially correlated with drug resistance in *P. vivax* parasite and the possible drug selection with time.

Methods: A total of 235 *P. vivax* samples were collected from patients suffering uncomplicated malaria at Yingjiang, Tengchong, and Longling counties, and Nabang port in China, Yunnan province, and Laiza township in Myanmar, during 2008 to 2017. Five potential drug resistance genes were amplified utilizing nested-PCR and analyzed, including *pvdhfr*, *pvdhps*, *pvmdr1*, *pvcrt-o*, and *pvk12*.

Results: The *pvdhfr* F57I/L, S58R, T61M and S117T/N presented in 40.64%, 56.68%, 40.11%, and 56.04% of the sequenced *P. vivax* isolates, and these mutations significantly decreased with years. The haplotype formed by these quadruple mutations predominated at Yingjiang, Tengchong, Longling and Nabang. While a mutation H99S/R (56.59%) dominated at Laiza and increased with time. In *pvdhps*, the A383G prevailed in 69.16% of the samples, which remained the most prevalent haplotype. However, a significant decrease of its occurrence was also noticed over the time. The S382A/C and A553G existed in 8.37% and 30.84% of the isolates, respectively. In *pvmdr1*, the mutation Y976F occurred at a low frequency in 5/232 (2.16%), while T958M was fixed and F1076L was approaching fixed (72.41%). The K10 insertion was detected at an occurrence of 33.17% in *pvcrt-o*, whereas there was no significant difference among the sites or over the time. No mutation was identified in *pvk12*.

Conclusions: Mutations related with resistance to antifolate drugs are prevalent in this area as expected, while their frequencies decrease significantly with time, suggestive of increased susceptibility of *P. vivax* parasite to antifolate drugs. Resistance to CQ is possibly emerging. However, since the molecular mechanisms underneath CQ resistance is yet to be better understood, close supervision of clinical drug efficiency and continuous function investigation is urgently needed to alarm drug resistance.

Background

Malaria has been a ghastly torment to human beings for millenniums and still infects 229 million people nowadays. Of the five species lead to human malaria, *Plasmodium falciparum* and *vivax* are two major causes. Africa suffers the most morbidity and mortality resulted from *P. falciparum*, while Southeast Asia accounts for the most *vivax* burden globally. In 2019, 51% of the world's 6.4 million *P. vivax* cases occurred in Southeast Asia (World Malaria Report. Geneva: WHO; 2020). The Greater Mekong Subregion (GMS) in Southeast Asia has targeted eliminating the menace of malaria by 2030. Of the six countries within GMS, malaria transmission levels are drastically various by country. Myanmar suffered the heaviest malaria load in 2016, whereas China reported no autochthonous malaria in 2017 and was certified indigenous malaria-free by the World Health Organization in 2021. However, China still faces the challenge of maintaining the control efforts because it shares a long border with Myanmar, involving 18

counties in Yunnan Province. Thus, the cross-border transmission of malaria remains a great risk to China. *P. vivax* is the predominant malaria species in the China-Myanmar border area, which caused the recent malaria outbreaks in 2013 and 2016 [1]. Despite the cause of these outbreaks is ambiguous, increased drug resistance might be one of the factors. It is therefore an urgent priority to supervise drug resistance in *P. vivax* on the China-Myanmar border.

Increasing reports have focused on drug resistance of *P. vivax* mainly to chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) regimens. CQ was first synthesized in 1934 and quickly proved to be a successful and important antimalarial agent [2]. It is now the most commonly administered drug for treating *P. vivax* infections. Other than the rapid resistance occurring in *P. falciparum* in 1950s, CQ resistant *P. vivax* was initially reported in late 1980s from Papua New Guinea [3] and Indonesia [4]. This was soon discovered in all around the world. High-level CQ-resistant *P. vivax* was reported in 1993 from north Myanmar [5], an area close to the southern border of China. In China, CQ has been used as the first-line drug to treat *P. vivax* along with primaquine to prevent relapse for nearly 60 years. Clinical failure or reduced efficacy of CQ-primaquine were reported in both border region [6] and the mainland [7]. SP is mainly applied in intermittent preventive treatment of malaria in pregnancy and infants, as well as in seasonal chemoprevention after its spread of resistance to *P. falciparum*. It still remains as a partner drug in artemisinin-based combination therapy (ACT) to treat sensitive *P. falciparum*. Albeit SP is not recommended to treat *P. vivax*, the common mixed-infection of *P. falciparum* and *vivax* in endemic area has introduced drug pressure and consequently selected SP-resistant isolates, which have been determined globally. Artemisinin resistance in *P. vivax* has not yet been reported, however, the emergence and spread of such resistance in *P. falciparum* has forewarned its appearance likely in *P. vivax*.

Molecular markers are efficient tools to monitor drug resistance. In *P. falciparum*, such markers are primarily manifested by mutant single nucleotide polymorphisms (SNPs) in related genes. CQ and SP resistance is correlated with chloroquine resistance transporter (CRT) gene and two genes encoding dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR) enzymes, respectively, while artemisinin resistance is associated with the kelch domain of K13 gene. In addition, multidrug resistance 1 (MDR1) gene is linked to resistance to multiple antimalarials as indicated by its name. However, identification of resistant markers in *P. vivax* is particularly challenging due to the limitation of *in vitro* culture. Consequently, investigation of vivax resistance markers is focused on the orthologs of those identified in *P. falciparum*, mainly including *pvdhfr*, *pvdhps* [8–10], *pvmdr1*, *pvcrt-o* [11, 12], as well as *pvk12* [13–15], the ortholog of *pfk13* gene. Indeed, studies have confirmed mutations F57I/L, S58R, T61M and S117N in *pvdhfr* are responsible for pyrimethamine resistance [9, 16–18], while S382A/C, A383G, and A553G in *pvdhps* are correlated with sulfadoxine resistance [19]. Albeit polymorphisms in codons 86, 184, 1034, 1042 and 1246 of the *pfmdr1* gene were reported to be associated with CQ resistance, only Y976F showed the association with decreased susceptibility to CQ, as well as to mefloquine and artemisinins [20–22]. However, the correlation of *pvcrt-o* with CQ resistance remains ambiguous. Survey of *pvcrt-o* gene failed in identifying its linkage with clinical CQ treatment failure[23], whereas analysis of mutant isoforms in yeast implies mutations in *pvcrt-o* might change the susceptibility of vivax parasite to CQ [24]. Similarly, the copy number of *pvcrt-o* was found correlated with

CQ resistance in Brazilian Amazon [25], while it was not observed in samples from Papua Indonesia [26]. Yet, the mechanism of CQ resistance still needs to be unveiled. Since the Kelch 13 (K13) gene in *P. falciparum* is considered as the main molecular marker of artemisinin resistance, likewise, its ortholog *pvk12* might be selected by drug pressure.

We report here the polymorphisms of these candidate drug resistant molecular markers, *pvdhfr*, *pvdhps*, *pvmdr1*, *pvcrt-o* and *pvk12*, in *P. vivax* from five sites along China–Myanmar Border during 2008 to 2017 to further understand their geographical distribution and potential selection over time.

Methods

Sample collection

Filter paper blood samples were collected from subjects attending local clinics with fever or other symptoms suggestive of malaria, during January 2008 to December 2017 at five sites on China-Myanmar border, including Yingjiang county, Tengchong county, Longling county, Nabang port in China, and Laiza township in Myanmar. The diagnosis of *P. vivax* infection was carried out by microscopic examination of Giemsa-stained thin and thick blood smears. Confirmed vivax malaria cases who consented to participate provided blood spots via standard finger-prick method. The spots were dried, numbered and sealed in plastic bags and stored at -20°C for later use.

Genomic DNA extraction, amplification and sequencing

Parasite genomic DNA was extracted using the Genomic DNA Extraction Kit (NanoMagBio, China) via a 96-well high-throughput nucleic acid extraction instrument (NanoMagBio, China) in accordance with the manufacturer's instructions. Genomic DNA was eluted in 50 µl of Tris- ethylene diamine tetraacetic acid (EDTA) buffer and stored at -20°C. Fragments of *pvdhfr* (755 bp), *pvdhps* (731 bp), *pvmdr1* (64 bp), *pvk12* (2108 bp) were amplified by nested PCR in 25 µl reaction volumes as previously described [27–29], while *pvcrt-o* (1272 bp) was amplified using regular PCR. One microliter of genomic DNA was applied as template for both nested and regular PCR in each reaction. The primers used in DNA amplification were listed in Additional file 1: Table S1. The PCR products were sequenced (Beijing TsingKe Biotech Co. Ltd., Beijing, China) commercially.

Sequence analysis

The nucleotide and deduced amino acid sequences were assembled, aligned and compared to the reference sequences from the NCBI database using DNAMAN software (version 9.0.1). Mutation analyses were conducted through MEGA software (version 10.0.5, <https://www.megasoftware.net/>). The accession numbers of reference sequences used in this study were as follows: *pvdhfr* (X98123), *pvdhps*

(XM001617159), *pvm-dr1* (AY618622), *pvcrt-o* (AF314649), and *pvk12* (PVX_083080). All sequences were submitted to GenBank (MZ960937 - MZ961394).

Statistical analysis

The percentile data were summarized utilizing Microsoft Excel 2015. The Chisq.test or Fisher's.test function in R language (version 3.5.3) were used to assess the frequency differences of mutations between years. Pearson's chi-square test was used to determine statistical significance ($P < 0.05$). If the data did not meet the assumptions of the chi-square test (80% of the cells having expected values of five or more, and no one cell having an expected value of less than one), an adjusted chi-square test and Fisher's exact test were therefore performed.

Results

The origins and clinical treatment of the cases

A total of 235 *P. vivax* infected patients suffering uncomplicated malaria during January 2008 to December 2017 were enrolled in this study, with 13 (5.53%) participating during 2008-2010, 31 (13.19%) through 2012-2015, and a majority (191, 81.28%) between 2016 and 2017. Eighty of these samples were collected from Laiza township in Myanmar, while the rest were from four sites in Yunnan province in China, including 91 from Yingjiang county, 41 from Longling county, 10 from Tengchong county and 13 from Nabang port. All patients were provided with anti-malarial therapy in accordance with the WHO guidelines for malaria treatment. Most cases (137, 58.30%) received 8-day chloroquine combined with 8-day primaquine regimen, while the rest were treated with 3-day chloroquine combined with 14-day primaquine (60, 25.53%) or a single dosage of naphthoquine phosphate (naphthoquine complexed with artemisinin, 35, 14.89%) (Table 1). DNA from their blood samples was used to amplify the *pvdhfr*, *pvdhps*, *pvm-dr1*, *pvcrt-o* and *pvk12* gene sequences, and resulted in 187, 227, 232, 199, and 138 sequences.

Table 1
General information of the enrolled cases.

General information	Case number (%)
Year	
2008-2010	13(5.53)
2012-2015	31(13.19)
2016-2017	191(81.28)
Gender	
Male	78(33.19)
Female	157(66.81)
Residence	
Laiza township	80(34.21)
Yingjiang county	91(38.72)
Longling county	41(17.59)
Tengchong county	10(4.26)
Nabang port	13(5.53)
Drug administration	
CQ(8 days)+Primaquine(8 days)	137(58.30)
CQ(3 days)+Primaquine(14 days)	60(25.53)
Compound naphthoquine tablet (single dosage)	35(14.89)
ACTs	1(0.43)
NR	2(0.85)
NR: No records	

Pvdhfr gene

Seven point mutations presented in *pvdhfr* gene, including C49R (1.07%), F57I/L (40.64%), S58R (56.68%), T61M (40.11%), H99S/R (56.59%), S117T/N (56.04%), and I173F (0.55%). Among these, the frequency of F57I/L, S58R, T61M and S117T/N decreased significantly with years, while H99S/R increased (Table 2). Haplotype analysis of *pvdhfr* revealed 11 distinct allelic forms, including the wild type (WT), haplotypes carrying a single mutation (58R, 99S, and 173F), double mutations (57L/58R and 58R/117N), triple mutations (57L/58R/61M), quadruple mutations (57I/58R/61M/117T and

57L/58R/61M/117T), and quintuple mutations (49R/57I/58R/61M/117T and 49R/57L/58R/61M/117T) (Table 3). Of note, the prevalence of haplotype containing a single mutation H99S differed significantly in samples across three time periods (0% vs 13.33% vs 33.33%, $P = 0.006$), indicating a recent selection of this mutation in this area.

Table 2
Prevalence of point mutations during different time periods.

Mutations#	Number of mutations (%)			
	2008-2010	2012-2015	2016-2017	Total
<i>pvdhfr</i>	<i>n=13</i>	<i>n=30</i>	<i>n=144</i>	<i>n=187</i>
C49R	1 (7.69)	0 (0)	1 (0.69)	2 (1.07)
F57I/L	11 (84.62)	18 (60.00)	47 (32.64)***	76 (40.64)
S58R	12 (92.31)	21 (70.00)	73 (50.69)**	106 (56.68)
T61M	11 (84.62)	17 (56.67)	47 (32.64)***	75 (40.11)
H99S/R	2 (15.38)	10 (33.33)	91 (63.19)***	103 (56.59)
S117T/N	12 (92.31)	19 (63.33)	71 (49.31)**	102 (56.04)
I173F	0 (0)	1 (3.33)	0 (0)	1 (0.55)
<i>pvdhps</i>	<i>n=13</i>	<i>n=30</i>	<i>n=184</i>	<i>n=227</i>
A372S	0 (0)	0 (0)	1 (0.54)	1 (0.44)
S382A/C	2 (15.38)	3 (10.00)	14 (7.61)	19 (8.37)
A383G	12 (92.31)	28 (93.33)	117 (63.59)***	157 (69.16)
K512E	0 (0)	1 (3.33)	11 (5.98)	12 (5.29)
A553G	8 (61.54)	16 (53.33)	46 (25.00)***	70 (30.84)
E571Q	0 (0)	0 (0)	9 (4.89)	9 (3.96)
G626A	0 (0)	0 (0)	4 (2.17)	4 (1.76)
A633S	0 (0)	0 (0)	3 (1.63)	3 (1.32)
D639E	0 (0)	0 (0)	9 (4.89)	9 (3.96)
S640G	0 (0)	0 (0)	9 (4.89)	9 (3.96)
A647S	0 (0)	1 (3.33)	32 (17.39)	33 (15.54)
<i>pvm^{dr}1</i>	<i>n=13</i>	<i>n=30</i>	<i>n=189</i>	<i>n=232</i>
T958M	13 (100)	30 (100)	189 (100)	232 (100)
Y976F	4 (30.77)	1 (3.33)	0 (0)	5 (2.16)

The difference in the mutations among three periods of time was calculated by Pearson's Chi-squared test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$

Point mutations are shown in boldface.

Mutations [#]	Number of mutations (%)			
K997R	0 (0)	1 (3.33)	7 (3.70)	8 (3.45)
F1076L	8 (61.54)	17 (56.67)	143 (75.66)	168 (72.41)
<i>pvcrt-o</i>	<i>n=12</i>	<i>n=29</i>	<i>n=158</i>	<i>n=199</i>
T2I	0 (0)	0 (0)	1 (0.63)	1 (0.50)
K10 insertion	7 (58.33)	11 (37.93)	48 (30.38)	66 (33.17)
R19 C	1 (8.33)	0 (0)	0 (0)	1 (0.50)
N57 H	0 (0)	1 (3.45)	0 (0)	1 (0.50)
The difference in the mutations among three periods of time was calculated by Pearson's Chi-squared test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$				
[#] Point mutations are shown in boldface.				

Table 3
Prevalence of *pvdhfr*, *pvdhps*, *pvm_{dr}1*, and *pvcrt-o* haplotypes

Gene	Type	Haplotype	Number of haplotype (%)			
			2008-2010	2012-2015	2016-2017	Total
	Wild type		1 (7.69)	4 (13.33)	23 (15.97)	28 (14.97)
	Single mutant (a)	58R	0 (0)	0 (0)	2 (0.69)	2 (0.53)
	Single mutant (b)	99S	0 (0)	4 (13.33)	48 (33.33)**	52 (27.81)
	Single mutant (c)	173F	0 (0)	1 (3.33)	0 (0)	1 (0.53)
	Double mutant	57L/58R	0 (0)	1 (3.33)	0 (0)	1 (0.53)
<i>pvdhfr</i>	Double mutant	58R/117N	1 (7.69)	3 (10.00)	23 (15.97)	27 (14.44)
	Triple mutant	57L/58R/61M	0 (0)	1 (3.33)	0 (0)	1 (0.53)
	Quadruple mutant (a)	57I/58R/61M/117T	5 (38.46)	9 (30.00)	28 (19.44)	42 (22.46)
	Quadruple mutant (b)	57L/58R/61M/117T	5(38.46)	7 (23.33)	18 (12.50)*	30 (16.04)
	Quintuple mutant (a)	49R/57I/58R/61M/117T	0 (0)	0 (0)	1 (0.69)	1 (0.53)
	Quintuple mutant (b)	49R/57L/58R/61M/117T	1 (7.69)	0 (0)	0 (0)	1 (0.53)
	Wild type		1 (7.69)	1 (3.33)	30 (16.30)	32 (14.10)
	Single mutant (a)	383G	4 (30.77)	7 (23.33)	63 (34.24)	74 (32.60)
	Single mutant (b)	553G	0 (0)	0 (0)	1 (0.54)	1 (0.44)
	Single mutant (c)	626A	0 (0)	3 (10.00)	1 (0.54)	4 (1.76)

The difference in the major haplotypes among three periods of time was calculated by corrected Pearson's Chi-squared test or Fisher exact test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

^a _ indicates no K10 insertion.

Gene	Type	Haplotype	Number of haplotype (%)			
	Single mutant (d)	647S	0 (0)	1 (3.33)	31 (16.84)	32 (14.10)
	Double mutant (a)	382A/383G	0 (0)	2 (6.66)	0 (0)*	2 (0.88)
<i>pvdhps</i>	Double mutant (b)	383G/553G	6 (46.15)	14 (46.67)	30 (16.30)***	50 (22.03)
	Double mutant (c)	512E/647S	0 (0)	0 (0)	1 (0.54)	1 (0.44)
	Double mutant (d)	626A/633S	0 (0)	0 (0)	2 (1.09)	2 (0.88)
	Triple mutant (a)	372S/626A/647S	0 (0)	0 (0)	1 (0.54)	1 (0.44)
	Triple mutant (b)	382A/383G/553G	2 (15.38)	1 (3.33)	5 (2.72)	8 (3.52)
	Triple mutant (c)	383G/512E/553G	0 (0)	1 (3.33)	1 (0.54)	2 (0.88)
	Quadruple mutant (a)	382C/383G/512E/553G	0 (0)	0 (0)	9 (4.86)	9 (3.96)
	Quadruple mutant (b)	383G/571Q/639E/640G	0 (0)	0 (0)	9 (4.89)	9 (3.96)
	Wild type		0 (0)	0 (0)	0 (0)	0 (0)
	Single mutant (a)	958M	5 (38.46)	12 (40.00)	39 (20.63)	56 (24.14)
	Double mutant (a)	958M/1076L	4 (30.77)	16 (53.33)	143 (75.66)***	162 (69.83)
	Double mutant (b)	958M/997R	0 (0)	1 (3.33)	6 (3.17)	7 (3.01)
<i>pvm-dr1</i>	Triple mutant (a)	958M/976F/1076L	4 (30.77)	1 (3.33)	0 (0)	5 (2.16)
	Triple mutant (b)	958M/997R/1076L	0 (0)	0 (0)	1 (0.53)	1 (0.43)
	Wild type		5 (41.67)	18 (62.07)	110 (69.62)	133 (66.83)

The difference in the major haplotypes among three periods of time was calculated by corrected Pearson's Chi-squared test or Fisher exact test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

^a _ indicates no K10 insertion.

Gene	Type	Haplotype	Number of haplotype (%)			
	Single mutant (a)	K10(in) ^a	6 (50.00)	10 (34.48)	47 (29.75)	63 (31.66)
<i>pvcrt-o</i>	Single mutant (b)	K10(in)/57H	0 (0)	1 (3.45)	0 (0)	1 (0.50)
	Single mutant (c)	K10(in)/19C	1 (5.08)	0 (0)	0 (0)	1 (0.50)
	Single mutant (d)	2I/K10(in)	0 (0)	0 (0)	1 (0.63)	1 (0.50)
The difference in the major haplotypes among three periods of time was calculated by corrected Pearson's Chi-squared test or Fisher exact test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.						
^a _ indicates no K10 insertion.						

The geographical haplotypes prevalence analysis demonstrated that the single mutant H99S was dominant at Laiza, while it was nearly absent from other sites. However, the haplotype harboring the quadruple mutations 57I/58R/61M/117T predominated in samples from Yingjiang, Tengchong and Longling. Its related haplotype with mutations 57L/58R/61M/117T prevailed in isolates from Nabang (Fig. 1a).

Three tandem repeat variations were detected in *pvdhfr* at positions 82 - 109. Type I was identical to the Sal I reference gene, type II contained a H99S mutation, and type III had a six amino-acid deletion at position 98-103 (THGGDN) (Fig. 1b). The prevalence of type I was significantly decreased with years, and vice versa for type II. Type III tended to increase over time, though without statistically evidence (Fig. 1c). Nevertheless, type II prevailed in Laiza but nearly absent from other regions in China (Fig. 1d).

Pvdhps gene

Alignment of the fragments of *pvdhps* gene discovered 11 mutations, including A372S, S382A/C, A383G, K512E, A553G, E571Q, G626A, A633S, D639E, S640G, and A647S. However, only two variants, A383G and A553G, were prevalent in the samples at an occurrence of 69.16% and 30.84%, respectively. The rest occurred at a relatively low frequency. The frequencies of A383G and A553G mutations significantly decreased with time (Table 2). This created 14 haplotypes containing WT and allelic forms harboring four single mutations (383G, 553G, 626A and 647S), four double mutations (382A/383G, 383G/553G, 512E/647S and 626A/633S), three triple mutations (372S/626A/647S, 382A/383G/553G and 383G/512E/553G), and two quadruple mutations (382C/383G/512E/553G and 383G/571Q/639E/640G). As expected, the haplotype with the single mutation A383G was the most prevalent one (32.60%), followed by A383G/A553G double mutations (22.03%) among all the *P. vivax* isolates. Interestingly, unlike the haplotype with only A383G mutation, the frequency of the haplotype with A383G/A553G significantly

decreased with time (Table 4). By site, A383G remained the predominated haplotype in samples from Tengchong and Yingjiang, and A383G/A553G prevailed in Tengchong and Longling (Fig. 2a).

Three tandem repeat variant types at position 603-637 were identified with a variable number of repeat unit 'G (E/D) (G/A) KLTN', much less than those reported previously in the same region [30]. Type a was identical to the Sal I reference sequence and carried five repeat units, type b had six units while type c held only three units (Fig. 2b). No statistical difference was found in the occurrence of these tandem repeat variations with years (Fig. 2c), however, type a remained the most common one in all sites, followed by type b (Fig. 2d).

Pvmdr1 gene

Four mutations at T958M, Y976F, K997R, and F1076L were observed in *pvmdr1* gene. The T958M mutation was fixed in all sequenced isolates, and the F1076L mutation was approaching fixed, occurring in 72.41% of the isolates. In contrast, Y976F and K997R happened in 5/232 (2.16%) and 8/232 (3.45%) (Table 2). This gave rise to five haplotypes comprised by a single mutation (958M), two double mutations (958M/1076L and 958M/997R), and two triple mutations (958M/976F/1076L and 958M/997R/1076L) (Table 5). It was noteworthy that the prevalence of the T958M/F1076L significantly increased over the three collection periods (30.77% vs 57.33% vs 75.66%, $P = 0.002$). Given that T958M was fixed in these samples, yet a recent selection of F1076L might have taken place in *P. vivax* in this region. Unsurprisingly, this 958M/1076L haplotype dominated in all of the sampling sites (Fig. 3a).

Pvcrt-o gene

Three mutations at codons 2, 19 and 57 (T2I, R19C and N57H) were detected and each occurred in one clinical isolate (Table 2). In addition, a K10 insertion was detected in 33.17% of the sequenced isolates. Thus, WT was the most prevalent haplotype (66.83%), followed by the K10 insertion (33.17%) among all sequenced *P. vivax* isolates (Fig. 3b).

Pvk12 gene

The 2108-bp amplified *pvk12* gene fragment contained 98.55% of the coding region. Hitherto, this gene remained conserved and no polymorphism was detected from *P. vivax* in this area.

Discussion

China has achieved the goal set in the National Malaria Elimination Action Plan (2010-2020) and eliminated indigenous malaria since 2017. However, border malaria remains a great concern because the risk for malaria reintroduction from the neighboring countries still exists. In particular, malaria along the China-Myanmar border area needs to be closely supervised due to the complex geographic conditions and migrant population. Antimalarial drug resistance could also jeopardize the recent gains. This study spotlighted the drug resistance in *P. vivax* at China-Myanmar border and investigated the polymorphisms

in those potential drug resistance genes to better understand their epidemic pattern, geographical distribution and possible recent selection.

The spread of antifolate drug resistance in *P. vivax* parasite from GMS has been widely reported and associated with point mutations in *pvdhfr* and *pvdhps* [10, 31, 32]. As expected, results from this study demonstrated high level resistance of vivax parasite to SP at China-Myanmar border. For *pvdhfr* gene, mutations F57I/L, S58R, T61M, S117N/T and I173L/F confer resistance to pyrimethamine [33]. Among these, S58R and S117N/T occur most frequently in highly resistant *P. vivax*, particularly, S117N/T is regarded as a drug resistance determinant [17]. The quadruple mutations F57(I/L)/S58R/T61M/S117T are likely related to high level pyrimethamine resistance and clinical treatment failure [34]. Our results presented that S58R and S117N/T mutations prevailed in 56.68% and 56.04% of the isolates, similar to those reported at the same region [30], but much lower than that detected in other areas of Myanmar (71–90%) [28] and Thailand border (100%) [27]. However, the frequency of these two mutations as well as the haplotype of F57L/S58R/T61M/S117T decreased significantly with time. It is possible that the susceptibility of *P. vivax* parasite to SP has increased after its withdrawal to treat the falciparum parasites which often co-infect the patients. The role of tandem repeat variation in *pvdhfr* remains ambiguous. Some reports indicate the sensitivity of vivax parasite to pyrimethamine is not related to the tandem repeats [35], because these variations occur outside of the substrate binding site [36]. Conversely, other studies report that a type of tandem repeat with four units might correlate with pyrimethamine drug resistance because of their co-existing with the quadruple 57I/58R/61M/117T mutations [37, 38]. Such type, however, was not found in this study.

Mutations S382A/C, A383G, and A553G in *pvdhps* are correlated with sulfadoxine resistance. Amongst these, mutations A383G and A553G might contribute more to the resistance, because they could cause a reduction in binding of sulfadoxine to *pvdhps* as confirmed in transgenic rodent parasites expressing *Pvdhps* protein [19, 39]. Here, we found A383G and A553G were prevailed in 69.16% and 30.84% of the isolates, respectively, similar to that reported by other studies [30]. Nevertheless, the prevalence of these two mutations significantly decreased with time, which could be another sign of increasing sensitivity of *P. vivax* parasites to SP in this region.

Recent studies monitored a decline in the therapeutic responses of *P. vivax* malaria to CQ treatment along China-Myanmar border [40, 41]. However, the molecular mechanism underlying CQ resistance in *P. vivax* remains to be fully understood. The genes *pvm-dr1* and *pvcrt-o* might be involved in CQ resistance [42]. In *pvm-dr1*, the *in vitro* sensitivity of *P. vivax* isolates carrying the Y976F shows a decrease to CQ [20, 21, 43]. This mutation is associated with CQ monotherapy failure as well [43]. The prevalence of Y976F is approaching fixation in vivax isolates from Indonesian Papua, however, here it was only detected in 2.16% of the samples, which is consistent with previous research in the same area [30]. The T958M mutation is fixed in this area, while it is confirmed irrelevant to the CQ resistance [30]. Likewise, few evidence supports the F1076L single mutation as a possible CQ resistance marker. The double mutations Y976F and F1076L are largely found from areas with CQ resistance, whereas the F1076L single mutation is more frequent in areas with rare CQ resistance [42, 44]. It is of interest that the double mutations Y976F

and F1076L were found only in samples from Tengchong and Longling in our study, alarming the emerging of CQ drug resistance in this border region.

The function of *pvcrt-o* gene in CQ resistance still needs to be fully understood. The lysine (K) insertion at codon 10 might be linked with decreased CQ sensitivity [7, 20]. K10 was observed in 33.17% of the sequenced samples here, while there was no significant difference among the sites or over the time. The copy number of *pvcrt-o* might be another factor affecting CQ treatment, which was found to be correlated with CQ resistance in Brazilian Amazon [25], but this was not observed in Papua Indonesia [26]. The expression level of *pvcrt-o* was not evaluated because dried blood spots were employed in the study. Yet, close supervision of the efficacy of CQ-primaquine regimen is important to monitor CQ resistance in this region.

Mutations in the propeller domain of *pfk13* are associated with reduced sensitivity to artemisinin and its derivatives in *P. falciparum* [45, 46]. Possibly, its orthologous gene in *P. vivax* parasite, *pvk12*, would be selected with artemisinin pressure. Hitherto, the *pvk12* gene remains conserved in this region, and only a few non-synonymous mutations were identified recently [47]. No mutation was detected in our samples, which is consistent with previous studies [15, 27]. Since CQ-primaquine remains the primary regimen to treat *P. vivax* in this area, artemisinin selection might have not yet developed.

Conclusions

This study reported the epidemic pattern and geographical distribution of five potential drug resistant markers, *pvdhfr*, *pvdhps*, *pvm-dr1*, *pvcrt-o* and *pvk12*, in *P. vivax* isolates from five sites along the China-Myanmar border during a 10-year period. Resistance to antifolate drugs is presented as expected in this area, however, the prevalence of certain mutations related to drug resistance decreased with time. Resistance to CQ is possibly emerging, therefore, close supervision of clinical drug efficiency and continuous function investigation is needed to better alarm drug resistance and direct vivax malaria treatment.

Abbreviations

P. vivax: *Plasmodium vivax*; ***pvdhfr***: *P. vivax* dihydrofolate reductase gene; ***pvdhps***: *P. vivax* dihydropteroate synthase gene; ***pvm-dr1***: *P. vivax* multidrug resistance 1 gene; ***pvcrt-o***: *P. vivax* chloroquine resistance transporter-o gene; ***pvk12***: *P. vivax* kelch 12 gene; **CQ**: chloroquine; **SP**: sulphadoxine-pyrimethamine; **ACT**: artemisinin-based combination therapy; **WHO**: World Health Organization; **GMS**: Greater Mekong Subregion; **SNPs**: single nucleotide polymorphisms; **CRT**: chloroquine resistance transporter; **DHPS**: dihydropteroate synthase; **DHFR**: dihydrofolate reductase; **MDR1**: multidrug resistance 1; **PCR**: polymerase chain reaction;

Declarations

Ethics approval and consent to participate

This study was approved by the Ethical Committee of the Institute of Pathogen Biology, Chinese Academy of Medical Sciences (IPB-2017-9).

Consent for publication

Not applicable.

Availability of data and materials

All sequences generated and analyzed during the current study were submitted to the GenBank (MZ960937 - MZ961394).

Competing interests

The authors declare that they have no competing interests.

Funding

This work has been supported by Major National Science and Technology Program of China for Innovative Drug (2017ZX09101002-001-001), CAMS Innovation Fund for Medical Sciences (CIFMS) (2017-I2M-3-016), and NHC Key Laboratory of Echinococcosis Prevention and Control (Project No.2020WZK2009).

Authors' contributions

WZS, WCY, PYC, WZH, JX, CQQ, ZLH conceived and designed the experiments. WZS, ZLH, JX, CQQ performed the experiments. WZS, WZL analyzed the data. WZS, WZL, WH wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgments

Not applicable.

References

1. Geng J, Malla P, Zhang J, Xu S, Li C, Zhao Y, et al. Increasing trends of malaria in a border area of the Greater Mekong Subregion. *Malar J*. 2019;18(1):309.
2. Wellems TE, Plowe CV. Chloroquine-resistant malaria. *J Infect Dis*. 2001;184(6):770-6.
3. Rieckmann KH, Davis DR, Hutton DC. *Plasmodium vivax* resistance to chloroquine? *Lancet*. 1989;2(8673):1183-4.
4. Baird JK, Basri H, Purnomo, Bangs MJ, Subianto B, Patchen LC, et al. Resistance to chloroquine by *Plasmodium vivax* in Irian Jaya, Indonesia. *Am J Trop Med Hyg*. 1991;44(5):547-52.

5. Myat Phone K, Myint O, Myint L, Thaw Z, Kyin Hla A, Nwe Nwe Y. Emergence of chloroquine-resistant *Plasmodium vivax* in Myanmar (Burma). *Trans R Soc Trop Med Hyg.* 1993;87(6):687.
6. Liang GL, Sun XD, Wang J, Zhang ZX. [Sensitivity of *Plasmodium vivax* to chloroquine in Laza City, Myanmar]. *Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi.* 2009;27(2):175-6.
7. Lu F, Lim CS, Nam DH, Kim K, Lin K, Kim TS, et al. Genetic polymorphism in *pvm-dr1* and *pvcrt-o* genes in relation to in vitro drug susceptibility of *Plasmodium vivax* isolates from malaria-endemic countries. *Acta Trop.* 2011;117(2):69-75.
8. Chulay JD, Watkins WM, Sixsmith DG. Synergistic antimalarial activity of pyrimethamine and sulfadoxine against *Plasmodium falciparum* in vitro. *Am J Trop Med Hyg.* 1984;33(3):325-30.
9. de Pecoulas PE, Tahar R, Ouatas T, Mazabraud A, Basco LK. Sequence variations in the *Plasmodium vivax* dihydrofolate reductase-thymidylate synthase gene and their relationship with pyrimethamine resistance. *Mol Biochem Parasitol.* 1998;92(2):265-73.
10. Imwong M, Pukrittayakamee S, Cheng Q, Moore C, Looareesuwan S, Snounou G, et al. Limited polymorphism in the dihydropteroate synthetase gene (*dhps*) of *Plasmodium vivax* isolates from Thailand. *Antimicrob Agents Chemother.* 2005;49(10):4393-5.
11. Nomura T, Carlton JM, Baird JK, del Portillo HA, Fryauff DJ, Rathore D, et al. Evidence for different mechanisms of chloroquine resistance in 2 *Plasmodium* species that cause human malaria. *J Infect Dis.* 2001;183(11):1653-61.
12. Rungsihirunrat K, Muhamad P, Chaijaroenkul W, Kuesap J, Na-Bangchang K. *Plasmodium vivax* drug resistance genes; *Pvmdr1* and *Pvcrt-o* polymorphisms in relation to chloroquine sensitivity from a malaria endemic area of Thailand. *Korean J Parasitol.* 2015;53(1):43-9.
13. Popovici J, Kao S, Eal L, Bin S, Kim S, Menard D. Reduced polymorphism in the Kelch propeller domain in *Plasmodium vivax* isolates from Cambodia. *Antimicrob Agents Chemother.* 2015;59(1):730-3.
14. Wang M, Siddiqui FA, Fan Q, Luo E, Cao Y, Cui L. Limited genetic diversity in the *PvK12* Kelch protein in *Plasmodium vivax* isolates from Southeast Asia. *Malar J.* 2016;15(1):537.
15. Deng S, Ruan Y, Bai Y, Hu Y, Deng Z, He Y, et al. Genetic diversity of the *Pvk12* gene in *Plasmodium vivax* from the China-Myanmar border area. *Malar J.* 2016;15(1):528.
16. Imwong M, Pukrittayakamee S, Looareesuwan S, Pasvol G, Poirriez J, White NJ, et al. Association of genetic mutations in *Plasmodium vivax dhfr* with resistance to sulfadoxine-pyrimethamine: Geographical and clinical correlates. *Antimicrob Agents Ch.* 2001;45(11):3122-7.
17. Imwong M, Pukrittayakamee S, Renia L, Letourneur F, Charlier JP, Leartsakulpanich U, et al. Novel point mutations in the dihydrofolate reductase gene of *Plasmodium vivax*: evidence for sequential selection by drug pressure. *Antimicrob Agents Chemother.* 2003;47(5):1514-21.
18. Tjitra E, Baker J, Suprianto S, Cheng Q, Anstey NM. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in *vivax* malaria pilot studies: Relationship to *Plasmodium vivax dhfr* mutations. *Antimicrob Agents Ch.* 2002;46(12):3947-53.

19. Korsinczky M, Fischer K, Chen NH, Baker J, Rieckmann K, Cheng Q. Sulfadoxine resistance in *Plasmodium vivax* is associated with a specific amino acid in dihydropteroate synthase at the putative sulfadoxine-binding site. *Antimicrob Agents Ch.* 2004;48(6):2214-22.
20. Suwanarusk R, Russell B, Chavchich M, Chalfein F, Kenangalem E, Kosaisavee V, et al. Chloroquine resistant *Plasmodium vivax*: in vitro characterisation and association with molecular polymorphisms. *PLoS One.* 2007;2(10):e1089.
21. Suwanarusk R, Chavchich M, Russell B, Jaidee A, Chalfein F, Barends M, et al. Amplification of *pvmr1* associated with multidrug-resistant *Plasmodium vivax*. *J Infect Dis.* 2008;198(10):1558-64.
22. del Carmen R, Vargas-Rodriguez M, Bastos MD, Menezes MJ, Orjuela-Sanchez P, Ferreira MU. Single-Nucleotide Polymorphism and Copy Number Variation of the Multidrug Resistance-1 Locus of *Plasmodium vivax*: Local and Global Patterns. *Am J Trop Med Hyg.* 2012;87(5):813-21.
23. Nomura T, Carlton JMR, Baird JK, del Portillo HA, Fryauff DJ, Rathore D, et al. Evidence for different mechanisms of chloroquine resistance in 2 *Plasmodium* species that cause human malaria. *Journal of Infectious Diseases.* 2001;183(11):1653-61.
24. Hassett MR, Riegel BE, Callaghan PS, Roepe PD. Analysis of *Plasmodium vivax* Chloroquine Resistance Transporter Mutant Isoforms. *Biochemistry-U.S.* 2017;56(41):5615-22.
25. Melo GC, Monteiro WM, Siqueira AM, Silva SR, Magalhaes BML, Alencar ACC, et al. Expression Levels of *pvcrt-o* and *pvmr-1* Are Associated with Chloroquine Resistance and Severe *Plasmodium vivax* Malaria in Patients of the Brazilian Amazon. *PLoS One.* 2014;9(8).
26. Pava Z, Handayani I, Wirjanata G, To S, Trianty L, Noviyanti R, et al. Expression of *Plasmodium vivax crt-o* Is Related to Parasite Stage but Not *Ex Vivo* Chloroquine Susceptibility. *Antimicrob Agents Ch.* 2016;60(1):361-7.
27. Tantiamornkul K, Pumpaibool T, Piriyaongsa J, Culleton R, Lek-Uthai U. The prevalence of molecular markers of drug resistance in *Plasmodium vivax* from the border regions of Thailand in 2008 and 2014. *Int J Parasitol Drugs Drug Resist.* 2018;8(2):229-37.
28. Nyunt MH, Han JH, Wang B, Aye KM, Aye KH, Lee SK, et al. Clinical and molecular surveillance of drug resistant *vivax* malaria in Myanmar (2009-2016). *Malar J.* 2017;16(1):117.
29. Liu H, Yang HL, Tang LH, Li XL, Huang F, Wang JZ, et al. Monitoring *Plasmodium vivax* chloroquine sensitivity along China-Myanmar border of Yunnan Province, China during 2008-2013. *Malar J.* 2014;13:364.
30. Zhao Y, Wang L, Soe MT, Aung PL, Wei H, Liu Z, et al. Molecular surveillance for drug resistance markers in *Plasmodium vivax* isolates from symptomatic and asymptomatic infections at the China-Myanmar border. *Malar J.* 2020;19(1):281.
31. Huang B, Huang S, Su XZ, Tong X, Yan J, Li H, et al. Molecular surveillance of *pvdhfr*, *pvdhps*, and *pvmr-1* mutations in *Plasmodium vivax* isolates from Yunnan and Anhui provinces of China. *Malar J.* 2014;13:346.
32. Hawkins VN, Auliff A, Prajapati SK, Rungsihirunrat K, Hapuarachchi HC, Maestre A, et al. Multiple origins of resistance-conferring mutations in *Plasmodium vivax* dihydrofolate reductase. *Malar J.*

2008;7:72.

33. Hawkins VN, Joshi H, Rungsihirunrat K, Na-Bangchang K, Sibley CH. Antifolates can have a role in the treatment of *Plasmodium vivax*. Trends Parasitol. 2007;23(5):213-22.
34. Hastings MD, Porter KM, Maguire JD, Susanti I, Kania W, Bangs MJ, et al. Dihydrofolate reductase mutations in *Plasmodium vivax* from Indonesia and therapeutic response to sulfadoxine plus pyrimethamine. J Infect Dis. 2004;189(4):744-50.
35. Asih PB, Marantina SS, Nababan R, Lobo NF, Rozi IE, Sumarto W, et al. Distribution of *Plasmodium vivax* pvdhfr and pvdhps alleles and their association with sulfadoxine-pyrimethamine treatment outcomes in Indonesia. Malar J. 2015;14:365.
36. Kongsaree P, Khongsuk P, Leartsakulpanich U, Chitnumsub P, Tarnchompoo B, Walkinshaw MD, et al. Crystal structure of dihydrofolate reductase from *Plasmodium vivax*: pyrimethamine displacement linked with mutation-induced resistance. Proc Natl Acad Sci U S A. 2005;102(37):13046-51.
37. Sharifi-Sarasiabi K, Haghighi A, Kazemi B, Taghipour N, Mojarad EN, Gachkar L. MOLECULAR SURVEILLANCE OF *Plasmodium vivax* AND *Plasmodium falciparum* DHFR MUTATIONS IN ISOLATES FROM SOUTHERN IRAN. Rev Inst Med Trop Sao Paulo. 2016;58:16.
38. Prajapati SK, Joshi H, Dev V, Dua VK. Molecular epidemiology of *Plasmodium vivax* anti-folate resistance in India. Malar J. 2011;10:102.
39. Pornthanakasem W, Riengrunroj P, Chitnumsub P, Ittarat W, Kongkasuriyachai D, Uthaipibull C, et al. Role of *Plasmodium vivax* Dihydropteroate Synthase Polymorphisms in Sulfa Drug Resistance. Antimicrob Agents Chemother. 2016;60(8):4453-63.
40. Yuan LL, Wang Y, Parker DM, Gupta B, Yang ZQ, Liu HE, et al. Therapeutic Responses of *Plasmodium vivax* Malaria to Chloroquine and Primaquine Treatment in Northeastern Myanmar. Antimicrob Agents Ch. 2015;59(2):1230-5.
41. Xu SL, Zeng WL, Mbenda HGN, Liu HE, Chen X, Xiang Z, et al. Efficacy of directly-observed chloroquine-primaquine treatment for uncomplicated acute *Plasmodium vivax* malaria in northeast Myanmar: A prospective open-label efficacy trial. Travel Med Infect Di. 2020;36.
42. Lu F, Wang B, Cao J, Sattabongkot J, Zhou H, Zhu G, et al. Prevalence of drug resistance-associated gene mutations in *Plasmodium vivax* in Central China. Korean J Parasitol. 2012;50(4):379-84.
43. Marfurt J, de Monbrison F, Brega S, Barbolat L, Muller I, Sie A, et al. Molecular markers of in vivo *Plasmodium vivax* resistance to amodiaquine plus sulfadoxine-pyrimethamine: mutations in pvdhfr and pvmdr1. J Infect Dis. 2008;198(3):409-17.
44. Khattak AA, Venkatesan M, Khatoon L, Ouattara A, Kenefic LJ, Nadeem MF, et al. Prevalence and patterns of antifolate and chloroquine drug resistance markers in *Plasmodium vivax* across Pakistan. Malar J. 2013;12:310.
45. Arie F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant *Plasmodium falciparum* malaria. Nature. 2014;505(7481):50-5.

The geographical distribution of tandem repeat variants . The size of the pie represents the number of the isolates (n).

Figure 2

Geographical prevalence of *pvdhps* haplotypes and tandem repeat variants. **a**, The geographical distribution of *pvdhps* haplotypes. **b**, Amino-acid sequence alignment of three tandem repeat variants. **c**, Frequency changes of tandem repeat variants over time. **d**, The geographical distribution of tandem repeat variants. The size of the pie represents the number of the isolates (n).

Figure 3

Geographical prevalence of *pvmdr1* haplotypes (**a**) and *pvcr1-o* haplotypes (**b**). The size of the pie represents the number of the isolates (n).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Graphicalabstract.jpg](#)
- [Additionalfile1.docx](#)